Overview

A Phase I Study to Investigate the Safety, Tolerability and PK of HLX60 (Anti-GARP Monoclonal Antibody) in Subjects With Solid Tumors or Lymphoma

Status:
Not yet recruiting
Trial end date:
2024-11-06
Target enrollment:
Participant gender:
Summary
This trial is an open, dose escalation phase I clinical study. Subjects can only enter this study after they meet the inclusion and exclusion criteria.Into subjects will accept HLX60 intravenous infusion, every 3 weeks, treatment until lose clinical benefit, toxicity, death, revocation of informed consent.
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai Henlius Biotech